TG Therapeutics (FRA:NKB2) Net Change in Cash : €39.4 Mil (TTM As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is TG Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

TG Therapeutics's Net Change in Cash for the three months ended in Sep. 2024 was €101.7 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was €39.4 Mil.

TG Therapeutics Net Change in Cash Historical Data

The historical data trend for TG Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Net Change in Cash Chart

TG Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

63.62

362.35

-225.27

-185.57

-8.58

TG Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Change in Cash	Get a 7-Day Free Trial															50.50	-53.16	-16.06	6.91	101.74

TG Therapeutics Net Change in Cash Calculation

TG Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-28.806	+	-46.447	+	66.67	+	0
	=	-8.6

TG Therapeutics's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -10.997 + -8.41 + 121.143 + 0

= 101.7

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €39.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of TG Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (FRA:NKB2) » Definitions » Net Change in Cash

Comparable Companies

KRYS IONS CRNX RNA CYTK VKTX ADMA BPMC ACLX CORT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE

Traded in Other Exchanges

TGTX:USA 0VGI:UK

Address

3020 Carrington Mill boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics Headlines

No Headlines